Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
- Conditions
- Toxic Epidermal Necrolysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT02319616
- Locations
- 🇺🇸
University of California, Davis Department of Dermatology, Sacramento, California, United States
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
- Conditions
- Bullous Pemphigoid
- Interventions
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 322
- Registration Number
- NCT02313870
- Locations
- 🇫🇷
University Hospital Of Montpellier, Montpellier, France
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: DFD06 Cream
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Promius Pharma, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT02131324
- Locations
- 🇺🇸
Advanced Research Associates, Glendale, Arizona, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Agave Clinical Research, LLC, Mesa, Arizona, United States
Comparison Between Corticosteroid and Topical Steroids in the DRESS
- Conditions
- Drug Rash With Eosinophilia and Systemic Symptoms
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 112
- Registration Number
- NCT01987076
- Locations
- 🇫🇷
Henri Mondor Hospital, Creteil, France
A Vasoconstriction Study With LEO 90100
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: LEO 90100 Aerosol, foamDrug: LEO 90100 Aerosol, foam, vehicleDrug: Daivobet® ointment
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 35
- Registration Number
- NCT01946386
- Locations
- 🇫🇷
CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 28
- Registration Number
- NCT01893567
- Locations
- 🇺🇸
Hamzavi Dermatology, Fort Gratiot, Michigan, United States
Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease
- Conditions
- Graft vs Host DiseaseOral Manifestations
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2012-10-03
- Target Recruit Count
- 28
- Registration Number
- NCT01699412
- Locations
- 🇧🇷
Hematology and Hemotherapy Center, Campinas, São Paulo, Brazil
🇧🇷Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil
Clobetasol for Oral Graft-Versus-Host Disease
- Conditions
- Oral Chronic Graft vs Host Disease
- Interventions
- Drug: Placebo oral rinse
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT01557517
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 41
- Registration Number
- NCT01453686
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
- Conditions
- Cutaneous Atrophy Due to Corticosteroids
- Interventions
- Drug: Placebo + Placebo
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 26
- Registration Number
- NCT01407471
- Locations
- 🇫🇷
Bichat Hospital, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.